Skip to content

Safety and protection of intramuscular rabies vaccine.

Assessing the safety and immunogenicity of shortened Essen regimen for post exposure prophylaxis against rabies.

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2014/08/004875
Enrollment
70
Registered
2014-08-13
Start date
Unknown
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Dog bites

Interventions

Intervention1: Shortened Essen Regimen for rabies prophylaxis: Injecting 1 dose of intramuscular anti rabies vaccine on days 0, 3, 7 & 14 (shortened Essen Regimen)for patients, where dog is healthy &

Sponsors

KIMS Hpspital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Healthy subjects with Category III exposures. If female, not pregnant or lactating at the time of enrolment and not planning pregnancy during the entire study period of 6 months. Previously unvaccinated/unexposed person. Willing to sign Informed consent to take 4 doses of IM vaccination (days 0, 3, 7 and 14), even when the dog is healthy and alive after 10 days. Subjects available for minimum of 6 months follow-up. Subjects willing to give blood samples on 4 recommended days i.e., on days 0, 14, 90 and 180.

Exclusion criteria

Exclusion criteria: Re exposure cases.

Design outcomes

Primary

MeasureTime frame
safety and Immunogenicity of new shortened Essen intramuscular regimenTimepoint: safety and Immunogenicity of new shortened Essen intramuscular regimen at the end of 6 months

Secondary

MeasureTime frame
Estimation of Rabies virus neutralizing antibodiesTimepoint: on Days 14, 90 & 365

Countries

India

Contacts

Public ContactDr Rupsa Banerjee

Kempegowda Institute of Medical Sciences

rupsabanerjee89@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026